FDA nominee Heidi Overton pledges faster, more efficient regulation to keep pace with China
During a Senate hearing, Heidi Overton was confirmed as the nominee to lead the U.S. Food and Drug Administration. She outlined her priorities for the agency.
Overton said the FDA must move faster and operate more efficiently to stay competitive with regulatory bodies in China. She emphasized that speed and streamlined processes are essential for protecting public health while supporting innovation.
The article also noted a new partnership between Eli Lilly and a Chinese entity, reflecting ongoing collaboration between U.S. pharma companies and China’s market.
This writeup was produced by pharmadog from original reporting by STAT. The original article may no longer be reachable at its published URL.
Original headline: “STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that